Drugs / MR-61
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07298824 Comparator | Oct 2025 → Jul 2027 expected | myopia | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR-61 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07298824 ↗ |
| Modality | Other / unclassified | “investigational probiotic powder MR-61” NCT07298824 ↗ |
| Route | Oral | “Oral administration” NCT07298824 ↗ |